{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/TGTX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-19T09:01:41.820Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9063,"canonical_name":"TG THERAPEUTICS, INC.","cik":"0001001316","uei":null,"lei":null,"duns":null,"ticker":"TGTX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"clinical":8,"sec":15},"count":23,"timeline":[{"ts":"2026-09-23","kind":"clinical.trial","reporter":"TG Therapeutics, Inc.","title":"Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07680946","excerpt":"[\"Schizophrenia\"]","importance":45},{"ts":"2026-09-22","kind":"clinical.trial","reporter":"TG Therapeutics, Inc.","title":"A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07673744","excerpt":"[\"Myasthenia Gravis\"]","importance":45},{"ts":"2026-09-14","kind":"sec.filing","form_type":"4","title":"4 — TG THERAPEUTICS, INC. — 2026-09-14","url_slug":"/sec/cik-0001001316/4/0001437749-26-030343","accession_number":"0001437749-26-030343","importance":30},{"ts":"2026-09-10","kind":"sec.filing","form_type":"144","title":"144 — TG THERAPEUTICS, INC. — 2026-09-10","url_slug":"/sec/cik-0001001316/144/0001959173-26-006866","accession_number":"0001959173-26-006866","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"4","title":"4 — TG THERAPEUTICS, INC. — 2026-08-07","url_slug":"/sec/cik-0001001316/4/0001437749-26-026608","accession_number":"0001437749-26-026608","importance":30},{"ts":"2026-08-07","kind":"sec.insider.g","reporter":"Charney Laurence N","title":null,"shares":500,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-08-07","kind":"sec.insider.g","reporter":"Charney Laurence N","title":null,"shares":450,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-08-06","kind":"sec.insider.g","reporter":"Charney Laurence N","title":null,"shares":5100,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-08-05","kind":"sec.filing","form_type":"10-Q","title":"10-Q — TG THERAPEUTICS, INC. — 2026-08-05","url_slug":"/sec/cik-0001001316/10-q/0001437749-26-025955","accession_number":"0001437749-26-025955","importance":45},{"ts":"2026-08-03","kind":"sec.filing","form_type":"8-K","title":"8-K — TG THERAPEUTICS, INC. — 2026-08-03","url_slug":"/sec/cik-0001001316/8-k/0001437749-26-025304","accession_number":"0001437749-26-025304","importance":35},{"ts":"2026-06-15","kind":"sec.filing","form_type":"4","title":"4 — TG THERAPEUTICS, INC. — 2026-06-15","url_slug":"/sec/cik-0001001316/4/0001437749-26-020679","accession_number":"0001437749-26-020679","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"4","title":"4 — TG THERAPEUTICS, INC. — 2026-06-15","url_slug":"/sec/cik-0001001316/4/0001437749-26-020673","accession_number":"0001437749-26-020673","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"4","title":"4 — TG THERAPEUTICS, INC. — 2026-06-15","url_slug":"/sec/cik-0001001316/4/0001437749-26-020675","accession_number":"0001437749-26-020675","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"4","title":"4 — TG THERAPEUTICS, INC. — 2026-06-15","url_slug":"/sec/cik-0001001316/4/0001437749-26-020676","accession_number":"0001437749-26-020676","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"4","title":"4 — TG THERAPEUTICS, INC. — 2026-06-15","url_slug":"/sec/cik-0001001316/4/0001437749-26-020677","accession_number":"0001437749-26-020677","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"8-K","title":"8-K — TG THERAPEUTICS, INC. — 2026-06-12","url_slug":"/sec/cik-0001001316/8-k/0001437749-26-020491","accession_number":"0001437749-26-020491","importance":35},{"ts":"2026-06-03","kind":"sec.filing","form_type":"8-K","title":"8-K — TG THERAPEUTICS, INC. — 2026-06-03","url_slug":"/sec/cik-0001001316/8-k/0001437749-26-019262","accession_number":"0001437749-26-019262","importance":35},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"TG Therapeutics, Inc.","title":"A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06680037","excerpt":"[\"B-cell Mediated Autoimmune Disorders\"]","importance":30},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"TG Therapeutics, Inc.","title":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07211633","excerpt":"[\"Relapsing Multiple Sclerosis\"]","importance":60},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"TG Therapeutics, Inc.","title":"A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)","security_title":null,"status":"RECRUITING","accession_number":"NCT06433752","excerpt":"[\"Relapsing Multiple Sclerosis\",\"Multiple Sclerosis\"]","importance":25},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"TG Therapeutics, Inc.","title":"An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04130997","excerpt":"[\"Relapsing Multiple Sclerosis (RMS)\"]","importance":60},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"TG Therapeutics, Inc.","title":"Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis","security_title":"PHASE2,PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07220252","excerpt":"[\"Relapsing Multiple Sclerosis\"]","importance":60},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"TG Therapeutics, Inc.","title":"Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07577583","excerpt":"[\"B-cell Mediated Autoimmune Disorders\"]","importance":25}]}